Telix Pharmaceuticals announced its third‑quarter 2025 results on Tuesday, 15 October 2025, reporting revenue of $206 million, a 53% year‑over‑year increase and a 1% sequential rise. PSMA imaging sales grew 17% to $155 million, while third‑party revenue from its RLS network reached $47 million, underscoring the company’s expanding commercial footprint.
The company highlighted that its two FDA‑approved PSMA imaging agents, Illuccix and Gozellix, continue to drive sales, with Gozellix reimbursement effective from 1 October under CMS’s Level II HCPCS and Transitional Pass‑Through codes. This regulatory milestone supports sustained demand for the company’s diagnostic portfolio.
Telix also raised its fiscal‑year 2025 sales guidance to a $800 million–$820 million range, up from the previous $770 million–$800 million band, reflecting stronger market traction and confidence in its growth trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.